| 81/401 | US=12 / Urologia Katz A. Alternative medicine for prostate cancer: diet, vitamins, minerals, and supplements. In: Su LM. Prostate cancer. Philadelphia: Elsevier Saunders, 2010. p. 207-28. (Early Diagnosis and Treatment of Cancer Series) ISBN 978-1-4160-4575-5. CANCER DE PROSTATA; MEDICINA ALTERNATIVA; DIETA; VITAMINAS; MINERAIS; SUPLEMENTACAO NUTRICIONAL; INGESTAO CALORICA; OBESIDADE; QUIMIOPREVENCAO |
| 82/401 | US=12 / Urologia Levinson AW. Controversies in prostate cancer. In: Su LM. Prostate cancer. Philadelphia: Elsevier Saunders, 2010. p. 229-50. (Early Diagnosis and Treatment of Cancer Series) ISBN 978-1-4160-4575-5. CANCER DE PROSTATA; DIETA; FINASTERIDA; CANCER DE PROSTATA. TRATAMENTO; BRAQUITERAPIA; TERAPIA ABLATIVA |
| 83/401 | US=9 / Urologia Schally AV, Block NL. Luteinizing hormone-releasing hormone and its agonistic, antagonistic, and targeted cytotoxic analogs in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 27-39. ISBN 978-1-60327-831-7. CANCER DE PROSTATA; SECRECAO DE LH; SECRECAO FSH; ESTEROIDES SEXUAIS; GONADOTROFINA; CASTRACAO QUIMICA; EFEITOS ANTICANCERIGENOS; CRESCIMENTO DO TUMOR; PROLIFERACAO CELULAR; RECEPTOR LHRH |
| 84/401 | US=9 / Urologia Prince DK, Hsing AW. Androgens and prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 53-9. ISBN 978-1-60327-831-7. CANCER DE PROSTATA; ANDROGENOS; TESTOSTERONA; TERAPIA DE REPOSICAO |
| 85/401 | US=9 / Urologia Gelmann EP. Androgen receptor biology in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 61-70. ISBN 978-1-60327-831-7. ANDROGENO RECEPTOR DE BIOLOGIA; CANCER DE PROSTATA; RECEPTOR DE ANDROGENO; ANDROGENO; MUTACAO; COATIVADOR; BETA-CATENINA; P160 |
| 86/401 | US=9 / Urologia Culig Z. 5-Alpha reductase inhibitors in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 83-9. ISBN 978-1-60327-831-7. CANCER DE PROSTATA; 5-ALFA REDUTASE; DUTASTERIDE; FINASTERIDE; ISOENZIMA |
| 87/401 | US=9 / Urologia Friedlander TW, Ryan CJ. Adrenal androgen synthesis inhibitor therapies in castration-resistant prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 91-100. ISBN 978-1-60327-831-7. SINTESE DE ANDROGENOS ADRENAIS; TERAPIAS INIBIDOR NA CASTRACAO-RESISTENTE; CANCER DE PROSTATA; TERAPIA HORMONAL SECUNDARIA; ANDROGENIOS ADRENAIS; ANDROGENO-INDEPENDENTES CANCER DE PROSTATA; CANCER DE PROSTATA HORMONIO REFRATARIO; FASE I; FASE I DE ENSAIOS CLINICOS; FARMACOCINETICA |
| 88/401 | US=9 / Urologia Sharifi N. Androgen deprivation therapy. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 101-7. ISBN 978-1-60327-831-7. TERAPIA DE PRIVACAO DE ANDROGENO; TERAPIA DE PRIVACAO DE ANDROGENO; ANDROGENOS; CANCER DE PROSTATA; TESTOSTERONA |
| 89/401 | US=9 / Urologia Marques FZC, Reichardt JKV. Pharmacogenetics of the androgen metabolic pathway. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 109-21. ISBN 978-1-60327-831-7. FARMACOGENETICA; ANDROGENOS; DOENCA MULTIFATORIAL; CANCER DE PROSTATA; CANCER DE PROSTATA. TRATRAMENTO; CANCER DE PROSTATA. PREVENCAO; CANCER DE PROSTATA. FARMACOGENETICA |
| 90/401 | US=9 / Urologia Halterman P, Vogelzang NJ, Farabishahadel A, Goodman Jr OB. Mitoxantrone. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 125-31. ISBN 978-1-60327-831-7. MITOXANTRONA; DHAD; CANCER DE PROSTATA; CRPC; TERAPIA DE RESGATE |
| 91/401 | US=9 / Urologia Sissung TM, Figg WD. Clinical pharmacology and pharmacogenetics of chemotherapy in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 163-77. ISBN 978-1-60327-831-7. FARMACOGENETICA DA QUIMIOTERAPIA. CANCER DE PROSTATA; FARMACOLOGIA CLINICA; DOCETAXEL; MITOXANTRONA; ESTRAMUSTINA; SATRAPLATIN; CANCER DE PROSTATA; FARMACOGENETICA; FARMACOLOGIA |
| 92/401 | US=9 / Urologia Fojo AT, Adelberg DE. Microtubule targeting agents. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 179-94. ISBN 978-1-60327-831-7. CITOESQUELETO; MICROTUBULOS; TUBULINA; QUIMIOTERAPIA; CANCER DE PROSTATA |
| 93/401 | US=109 / Câncer Oh WK, Ross R, Choueiri TK, Kantoff PW, Corless C. Cancer of the genitourinary tract. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 233-77. ISBN 978-0-323-05905-3. CANCER DO TRATO GENITURINARIO; CANCER DE PROSTATA; CANCER DE BEXIGA; CANCER DE RIM; CANCER TESTICULAR; CANCER DE PENIS |
| 94/401 | US=9 / Urologia Elfiky AA, Kelly WK. Bevacizumab in advanced prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 207-14. ISBN 978-1-60327-831-7. BEVACIZUMAB IN ADVANCED PROSTATE CANCER; ANGIOGENESE; CANCER DE PROSTATA; DROGAS; BEVACIZUMAB |
| 95/401 | US=9 / Urologia Gardner ER, Di Lorenzo G, Figg WD. Thalidomide and analogs. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 215-23. ISBN 978-1-60327-831-7. TALIDOMIDA; LENALIDOMIDA; ANGIOGENESE; CANCER DE PROSTATA; IMUNOMODULADORES |
| 96/401 | US=9 / Urologia Aragon-Ching JB, Dahut W. Investigational angiogenesis inhibitors. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 225-32. ISBN 978-1-60327-831-7. INIBIDORES DA ANGIOGENESE; ANTIANGIOGENESIS; ENSAIOS CLINICOS; CANCER DE PROSTATA; TIROSINA QUINASES |
| 97/401 | US=9 / Urologia Keller ET, Hall CL. Pathophysiology of prostate cancer bone metastasis. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 245-54. ISBN 978-1-60327-831-7. FISIOPATOLOGIA DA PROSTATA; METASTASE OSSEA DO CANCER; CANCER DE PROSTATA; METASTASE OSSEA; RANKL; PROTEINA MORFOGENETICA OSSEA |
| 98/401 | US=9 / Urologia Sartor O, Venugopal DR. Radiopharmaceuticals. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 255-66. ISBN 978-1-60327-831-7. RADIOFARMACOS; SAMARIO-EDTMP; CLORETO DE ESTRONCIO; RADIO; FOSFORO; PALIACAO; CANCER DE PROSTATA; METASTASES OSSEAS; TERAPIA OSSO-ALVO |
| 99/401 | US=9 / Urologia Saylor PJ, Smith MR. Bisphosnates for prevention and treatment of bone metastases. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 267-75. ISBN 978-1-60327-831-7. CANCER DE PROSTATA; METASTASES OSSEAS; ODANACATIB; OSTEOCLASTOS; BISFOSFONATO; ESQUELETICOS RELACIONADOS COM EVENTOS; DENOSUMAB |
| 100/401 | US=9 / Urologia Nelson JB. Endothelin receptors as therapeutic targets in castration-resistant prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 277-86. ISBN 978-1-60327-831-7. RECEPTORES DE ENDOTELINA; CASTRACAO CANCER DE PROSTATA. TERAPIAS; METASTASES OSSEAS; ENSAIOS CLINICOS; RECEPTORES DE ENDOTELINA; ENDOTELINA-1; CANCER DE PROSTATA |